304 related articles for article (PubMed ID: 15992586)
21. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
22. 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.
Enguehard-Gueiffier C; Hübner H; El Hakmaoui A; Allouchi H; Gmeiner P; Argiolas A; Melis MR; Gueiffier A
J Med Chem; 2006 Jun; 49(13):3938-47. PubMed ID: 16789750
[TBL] [Abstract][Full Text] [Related]
23. Dopamine D2-like receptor agonists induce penile erection in male rats: differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus.
Sanna F; Succu S; Hübner H; Gmeiner P; Argiolas A; Melis MR
Behav Brain Res; 2011 Nov; 225(1):169-76. PubMed ID: 21784104
[TBL] [Abstract][Full Text] [Related]
24. Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus.
Floran B; Floran L; Erlij D; Aceves J
Eur J Pharmacol; 2004 Sep; 498(1-3):97-102. PubMed ID: 15363981
[TBL] [Abstract][Full Text] [Related]
25. The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.
Kuzhikandathil EV; Bartoszyk GD
Neuropharmacology; 2006 Sep; 51(4):873-84. PubMed ID: 16844149
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.
Kesten SR; Heffner TG; Johnson SJ; Pugsley TA; Wright JL; Wise LD
J Med Chem; 1999 Sep; 42(18):3718-25. PubMed ID: 10479303
[TBL] [Abstract][Full Text] [Related]
27. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
Unangst PC; Capiris T; Connor DT; Doubleday R; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
J Med Chem; 1997 Dec; 40(25):4026-9. PubMed ID: 9406594
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
[TBL] [Abstract][Full Text] [Related]
29. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
30. Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation.
Bitner RS; Nikkel AL; Otte S; Martino B; Barlow EH; Bhatia P; Stewart AO; Brioni JD; Decker MW; Moreland RB
Neuropharmacology; 2006 Apr; 50(5):521-31. PubMed ID: 16324724
[TBL] [Abstract][Full Text] [Related]
31. Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells.
McAllister G; Knowles MR; Ward-Booth SM; Sinclair HA; Patel S; Marwood R; Emms F; Patel S; Smith A; Seabrook GR
J Recept Signal Transduct Res; 1995; 15(1-4):267-81. PubMed ID: 8903944
[TBL] [Abstract][Full Text] [Related]
32. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
Cowart M; Latshaw SP; Bhatia P; Daanen JF; Rohde J; Nelson SL; Patel M; Kolasa T; Nakane M; Uchic ME; Miller LN; Terranova MA; Chang R; Donnelly-Roberts DL; Namovic MT; Hollingsworth PR; Martino BR; Lynch JJ; Sullivan JP; Hsieh GC; Moreland RB; Brioni JD; Stewart AO
J Med Chem; 2004 Jul; 47(15):3853-64. PubMed ID: 15239663
[TBL] [Abstract][Full Text] [Related]
34. Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).
Moreland RB; Nakane M; Donnelly-Roberts DL; Miller LN; Chang R; Uchic ME; Terranova MA; Gubbins EJ; Helfrich RJ; Namovic MT; El-Kouhen OF; Masters JN; Brioni JD
Biochem Pharmacol; 2004 Aug; 68(4):761-72. PubMed ID: 15276084
[TBL] [Abstract][Full Text] [Related]
35. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain.
Sóvágó J; Makkai B; Gulyás B; Hall H
Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196
[TBL] [Abstract][Full Text] [Related]
36. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
[TBL] [Abstract][Full Text] [Related]
37. Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
Gyertyán I; Kiss B; Gál K; Laszlovszky I; Horváth A; Gémesi LI; Sághy K; Pásztor G; Zájer M; Kapás M; Csongor EA; Domány G; Tihanyi K; Szombathelyi Z
J Pharmacol Exp Ther; 2007 Mar; 320(3):1268-78. PubMed ID: 17170312
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
39. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
[TBL] [Abstract][Full Text] [Related]
40. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
Hamacher A; Weigt M; Wiese M; Hoefgen B; Lehmann J; Kassack MU
BMC Pharmacol; 2006 Sep; 6():11. PubMed ID: 16978403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
